CELU - Celularity Appoints Geoffrey Shiu Fei Ling M.D. Ph.D. to its Board of Directors | Benzinga
FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need.
Throughout his career, Dr. Ling has made significant contributions to regenerative medicine and stem cell therapy, earning him recognition as a thought leader in these areas. He has published numerous research papers on innovative cellular therapies. His profound understanding of the intricate biological processes underpinning cell-based treatments makes him an ideal addition to Celularity's Board of Directors. Leveraging Dr. Ling's outside perspective and deep expertise in stem cell therapy, Celularity hopes to unlock the full potential of placental-derived cells and tissues.
"We are honored to welcome Geoff to the Celularity Board of Directors," said Robert J. Hariri, M.D., Ph.D., founder, Chairman and Chief Executive Officer of Celularity. "We believe Geoff's decades-long success record in academia, the military, government and the biopharmaceutical industry will serve Celularity well as we look to progress our pipeline of investigational products to deliver ‘off-the-shelf' cellular and regenerative therapies faster, more reliably, and at greater scale to more patients. I have long admired Geoff's career and contributions to medicine and biotechnology, his service to our nation, and have been privileged to share some common background in our careers."
Dr. Ling commented on his new role, "I am thrilled to join the board of Celularity, a company known for its groundbreaking work in cellular therapies. I look forward to collaborating with my fellow board members and the talented team at Celularity to further advance the development of transformative treatments that have the potential to change lives."
Dr. Ling brings more than 30 years of experience in pharmaceutical, governmental, and academic organizations to his new role. Most recently, he co-founded On Demand Pharmaceuticals – developing advanced, miniaturized, and automated pharmaceutical manufacturing systems that create from precursors to final ...